EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

PEGylated therapeutics in the clinic

Yongsheng Gao iD, Maithili Joshi iD, Zongmin Zhao iD, Samir Mitragotri iD

Bioengineering & Translational Medicine · 2024-01 · 9 (1)

DOI: 10.1002/btm2.10600 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Bioengineering & Translational Medicine, online erschienen am 22.09.2023. Verfasst von Yongsheng Gao und 3 weiteren Autor:innen. Beteiligte Einrichtung: John A. Paulson School of Engineering and Applied Sciences, Harvard University Allston Massachusetts USA. Die Arbeit wurde bisher 248-mal zitiert (Crossref) und nennt 142 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, Harvard School of Engineering and Applied Sciences, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The covalent attachment of polyethylene glycol (PEG) to therapeutic agents, termed PEGylation, is a well‐established and clinically proven drug delivery approach to improve the pharmacokinetics and pharmacodynamics of drugs. Specifically, PEGylation can improve the parent drug's solubility, extend its circulation time, and reduce its immunogenicity, with minimal undesirable properties. PEGylation technology has been applied to various therapeutic modalities including small molecules, aptamers, peptides, and proteins, leading to over 30 PEGylated drugs currently used in the clinic and many investigational PEGylated agents under clinical trials. Here, we summarize the diverse types of PEGylation strategies, the key advantages of PEGylated therapeutics over their parent drugs, and the broad applications and impacts of PEGylation in clinical settings. A particular focus has been given to the size, topology, and functionalities of PEG molecules utilized in clinically used PEGylated drugs, as well as those under clinical trials. An additional section has been dedicated to analyzing some representative PEGylated drugs that were discontinued at different stages of clinical studies. Finally, we critically discuss the current challenges faced in the development and clinical translation of PEGylated agents.

Schlagwörter

Stichwörter der Autor:innen

FDAPEGylationclinicclinical translationclinical trialdrug deliverylong‐acting drugspolymer–drug conjugatesprotein modification

Autor:innen und Institutionen

  • John A. Paulson School of Engineering and Applied Sciences, Harvard University Allston Massachusetts USA.
  • Wyss Institute for Biologically Inspired Engineering at Harvard University Boston Massachusetts USA.
  • Present address: Department of Bioengineering The University of Texas at Dallas Richardson TX USA.
  • Department of Pharmaceutical Sciences College of Pharmacy, University of Illinois at Chicago Chicago Illinois USA.

ORCID-Profile: Yongsheng Gao, Maithili Joshi, Zongmin Zhao, Samir Mitragotri

Förderung

  • NIGMS NIH HHS
  • Harvard School of Engineering and Applied Sciences
  • National Institutes of Health

Zitieren

APA

Gao, Y., Joshi, M., Zhao, Z., & Mitragotri, S. (2024). PEGylated therapeutics in the clinic. Bioengineering & Translational Medicine, 9(1). https://doi.org/10.1002/btm2.10600

Vancouver

Gao Y, Joshi M, Zhao Z, Mitragotri S. PEGylated therapeutics in the clinic. Bioengineering & Translational Medicine. 2024;9(1). doi:10.1002/btm2.10600

BibTeX
@article{Gao2024,
  author = {Gao, Yongsheng and Joshi, Maithili and Zhao, Zongmin and Mitragotri, Samir},
  title = {PEGylated therapeutics in the clinic},
  journal = {Bioengineering & Translational Medicine},
  year = {2024},
  volume = {9},
  number = {1},
  doi = {10.1002/btm2.10600}
}
Kostenlos starten →